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Motivation: High-throughput sequencing of large immune repertoires has enabled the de-
velopment of methods to predict the probability of generation by V(D)J recombination of T-
and B-cell receptors of any specific nucleotide sequence. These generation probabilities are very
non-homogeneous, ranging over 20 orders of magnitude in real repertoires. Since the function of a
receptor really depends on its protein sequence, it is important to be able to predict this probability
of generation at the amino acid level. However, brute-force summation over all the nucleotide
sequences with the correct amino acid translation is computationally intractable. The purpose of
this paper is to present a solution to this problem.
Results: We use dynamic programming to construct an efficient and flexible algorithm, called
OLGA (Optimized Likelihood estimate of immunoGlobulin Amino-acid sequences), for calculating
the probability of generating a given CDR3 amino acid sequence or motif, with or without V/J
restriction, as a result of V(D)J recombination in B or T cells. We apply it to databases of
epitope-specific T-cell receptors to evaluate the probability that a typical human subject will
possess T cells responsive to specific disease-associated epitopes. The model prediction shows an
excellent agreement with published data. We suggest that OLGA may be a useful tool to guide
vaccine design.
Availability: Source code is available at https://github.com/zsethna/OLGA
I. INTRODUCTION
The ability of the adaptive immune system to recognize
foreign peptides, while avoiding self peptides, depends
crucially on the specificity of receptor-antigen binding
and the diversity of the receptor repertoire. Immune
repertoire sequencing (Repseq) of B- and T-cell recep-
tors (BCR and TCR) [16, 21, 39, 46] offers an efficient
experimental tool to probe the diversity of full repertoires
in healthy individuals [11, 18, 26, 28, 32, 33, 45], in co-
horts with specific conditions [4, 9, 10, 17, 19, 20, 29, 43]
and evaluate the response to specific fluorescent MHC-
multimers [2, 14]. Recent work has shown that re-
sponding clonotypes often form disjoint clusters of similar
amino acid sequences, which has lead to the identification
of responsive amino acid motifs [2, 14]. In order for these
techniques to have practical applications in therapy and
vaccine design, one needs a fast and efficient algorithm
to evaluate which specific amino acid sequences and se-
quence motifs are likely to be generated and found in
repertoires. We present a solution to this problem in
the form of an algorithm and computational tool, called
OLGA, which implements an exact computation of the
generation probability of any BCR or TCR sequence (nu-
cleotide or amino acid), or motif.
BCR and TCR are stochastically generated by choos-
ing a germline genetic template in each of several cas-
settes of alternates (V, (D), or J) and then splicing them
together with random nucleotide deletions and insertions
at the junctions. Given a generative model, one can
define the generation probability of any nucleotide se-
quence as the sum of the probabilities of all the genera-
tive events that can produce that sequence [6, 7, 25, 27].
However, computing the generation probability of amino
acid sequences by summing over all consistent nucleotide
sequences is impractical: because of codon degeneracy,
the number of nucleotide sequences to be summed grows
exponentially with sequence length. OLGA is powered
by an efficient dynamic programming method to exactly
sum over generative events and obtain net probabilities
of amino acid sequences and motifs.
We validate our algorithm by comparing its results and
performance to Monte-Carlo sampling estimates. We
present results using publicly available data for both
TCR α (TRA, Pogorelyy et al. [28]) and β (TRB, Robins
et al. [33]) chains and BCR heavy chains (IGH, DeWitt
et al. [3] of humans), and TRB of mice [35]. We ap-
plied OLGA to a TCR database that catalogs the dif-
ferent CDR3 amino acid sequences responding to a vari-
ety of different epitopes associated with disease [37]. We
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2computed the generation probability of particular CDR3
amino acid sequences, as well as the net generation prob-
ability of all the TCR that respond to a particular epi-
tope. Finally, we discuss OLGA’s applications in vaccine
design and other therapeutic contexts.
II. METHODS
A. Stochastic model of VDJ recombination
V(D)J recombination is a stochastic process involving
several events (gene template selection, terminal dele-
tions from the templates, random insertions at the junc-
tions), each of which has a set of possible outcomes cho-
sen according to a discrete probability distribution. The
probability P recgen(E) of any generation event E, defined
as a combination of the above-mentioned processes is,
for the TRB locus:
P recgen(E) = PV(V )PDJ(D,J)PdelV(dV |V )PdelJ(dJ |J)
× PdelD(dD, d′D|D)PinsVJ(`VD)p0(m1)
[
`VD∏
i=2
SVD(mi|mi−1)
]
× PinsDJ(`DJ)q0(n`DJ )
[
`DJ−1∏
i=1
SDJ(ni|ni+1)
]
,
(1)
where (V,D, J) identify the choices of gene templates,
(dV , dD, d
′
D, dJ) are the numbers of deletions at each end
of the segments, and (m1, . . . ,m`VD ) and (n1, . . . , n`DJ )
are the untemplated inserted nucleotide sequences at the
VD and DJ junctions. These variables specify the re-
combination event E, and are drawn according to the
probability distributions (PV, PDJ, PdelV, PdelD, PdelJ,
PinsVJ, PinsDJ, p0, q0, SVD, SDJ). The inserted segments
are drawn according to a Markov process starting with
the nucleotide distribution p0 and with the transition ma-
trix R, and running from the 5’ side (left to right) for the
VD segment, and from the 3’ side (right to left) from the
DJ segment. Similar models can be defined for the α
chain or for BCR chains. Although here we describe the
method for TRB only, it is also implemented for other
chains in the software.
Since the same nucleotide sequence can be created by
more than one specific recombination event, the gener-
ation probability of a nucleotide sequence is the sum
of the probabilities of all possible events that generate
the sequence: P ntgen(σ) =
∑
E→σ P
rec
gen(E), where the sum
is over all recombination events E that produce the se-
quence σ = (σ1, . . . , σn). The probability of generation
of an amino acid sequence, a = (a1, . . . , aL) is the sum of
the probabilities of all nucleotide sequences that translate
into the amino acid sequence:
P aagen(a1, . . . , aL) =
∑
σ∼a
P ntgen(σ1, ., σ3L) =
∑
E→σ∼a
P recgen(E),
(2)
} } }} }
Vx1 D(D)x2x3 J (D)x4
Mx1x2 N x3x4
N2N1
V D Jx1 x2 x3 x4
FIG. 1: Partitioning a CDR3 sequence: boxes correspond to
nucleotides and are indexed by integers. Each group of three
boxes (identified by heavier boundary lines) corresponds to an
amino acid. The nucleotide positions x1, . . . , x4 identify the
boundaries between different elements of the partition. The
V,M, D(D), N and J (D) matrices define cumulated weights
corresponding to each of the 5 elements.
where the ∼ sign indicates that σ translates into a. We
can generalize this approach to any scheme that groups
nucleotide triplets, or codons, into arbitrary classes,
which we still denote by σ ∼ a. In the formulation above,
these classes simply group together codons with the same
translation according to the standard genetic code. In an
example of generalization, all codons that code for amino
acids with a common chemical property, e.g. hydropho-
bicity or charge, could be grouped into a single class.
In that formulation, (a1, . . . , aL) would correspond to a
sequence of symbols denoting that property. More gen-
erally, any grouping of amino acids can be chosen (in-
cluding one where any amino acid is acceptable), and
the partition can be position dependent. Thus, the gen-
eration probability of arbitrary “motifs” can be queried.
In the following, for ease of exposition, we restrict our
attention to the case where a is an amino acid sequence.
B. Dynamic programming computation of the
generation probability of amino acid sequences
We now give an overview of how OLGA computes Eq. 2
without performing the sum explicitly, using dynamic
programming. Fig. S1-S2 give a graphical overview of
the method, and details of the method implementation
can be found in SI Secs. I and II and in the code man-
ual. Given the genomic nucleotide sequences of the possi-
ble gene templates, together with a specific model of the
type described in Eq. A1, the algorithm computes the net
probability of generating a recombined gene with a given
CDR3 amino acid sequence under a given set of V and J
gene choices.
Each recombination event implies an annotation of the
CDR3 sequence, assigning a different origin to each nu-
cleotide (V, N1, D, N2, or J, where N1 and N2 are the
VD and DJ insertion segments, respectively) that parses
the sequence into 5 contiguous segments (see schematic
in Fig. 1). The principle of the method is to sum over the
probabilities of all choices of nucleotides consistent with
the known amino acid sequence, over the possible loca-
tions of the 4 boundaries (x1, x2, x3, and x4) between the
5 segments, and over the possible V, D, and J genomic
templates (Fig. 1). We do this in a recursive way using
3matrix operations by defining weights that accumulate
the probabilities of events from the left of a position x
(i.e. up to x), and weights that accumulate events from
the right of x (i.e. from x + 1 on). Specifically, we de-
fine the following index notation: Xx with a subscript
called left index, accumulates weights from the left of x;
Yx, with a superscript called right index, accumulates
weights from the right of x; a matrix X xy corresponds
to accumulated weights from position x+ 1 to y (as will
be explained shortly, these objects may have suppressed
nucleotide indices as well). P aagen is calculated recursively
by matrix-like multiplications as:
P aagen(a) =
∑
x1,x2,x3,x4
Vx1Mx1x2
∑
D
[D(D)x2x3N x3x4J (D)x4] .
(3)
The vector Vx corresponds to a cumulated probability of
the V segment finishing at position x;Mxy is the proba-
bility of the VD insertion extending from x+1 to y; N xy
is the same for DJ insertions; Dxy(D) corresponds to
weights of the D segment extending from x+ 1 to y, con-
ditioned on the D germline choice being D; J x(D) gives
the weight of J segments starting at position x+1 condi-
tioned on the D germline being D. This D dependency
is necessary to account for the dependence between the
D and J germline segment choices [27]. All the defined
vectors and matrices depend implicitly on the amino acid
sequence (a1, . . . , aL), but we leave this dependency im-
plicit to avoid making the notation too cumbersome.
Because we are dealing with amino acid sequences en-
coded by triplet nucleotide codons, we need to keep track
of the identity of the nucleotide at the beginning or the
end of a codon. Depending on the position of the index
x in the codon, the objects defined above may be vectors
of size 4 (or 4× 4 matrices) in the suppressed nucleotide
index. We use conventions that depend on whether we
are considering left or right indices, as follows.
If x is a multiple of 3, i.e. x = 0 (mod 3), then we
do not keep nucleotide information and both Xx and
Yx are scalars (whether x is a left or a right index). If
x = 1 (mod 3), then Xx must be interpreted as a row vec-
tor of 4 numbers, Xx(σ), σ = A, T,G,C, corresponding
to the cumulated probability weight that the nucleotide
at position x (first position of the codon) takes value
σ. If x = 2 (mod 3), then Xx is also a row vector of 4
numbers, Xx(σ), but with a different interpretation: it
corresponds to the cumulated probability up to position
x, with the additional constraint that the nucleotide at
position x + 1 (the last position in the codon) can take
value σ (the value is 0 otherwise). For right indices, the
interpretation is reversed and the entries are column vec-
tors: when x = 1 (mod 3) the Yx is a column vector
containing the cumulated weights from x + 1 onwards,
with the constraint that the nucleotide at x can be σ,
and when x = 2 (mod 3), it is the probability weight
that the nucleotide at position x + 1 is σ. Generalizing
to matrices, X xy is a 4x4, 4x1, 1x4, or 1x1 matrix de-
pending on whether the x and y positions are multiples
of 3 or not, with the same rules as for vectors for each
type of index.
Entries with left indices are interpreted as row vectors,
and entries with right indices as column vectors. Thus,
in Eq. B2 contractions between left and right indices cor-
respond to dot products over the 4 nucleotides when the
index is not a multiple of 3, and simply a product of
scalars when it is.
The entries of the matrices corresponding to the
germline segments, V, D(D), and J (D), can be calcu-
lated by simply summing over the probabilities of dif-
ferent germline nucleotide segments compatible with the
amino acid sequence (a1, . . . , aL) with conditions on dele-
tions to achieve the required segment length. For in-
stance, the V matrix elements are given by:
Vx(σ) =
∑
V
PV(V )PdelV(lV−x)I(sVx =σ)I(sV1:x ∼ a1:i) if u = 1
Vx(σ) =
∑
V
PV(V )PdelV(lV−x)I((sV1:x, σ) ∼ a1:i) if u = 2,
Vx =
∑
V
PV(V )PdelV(lV −x)I(sV1:x ∼ a1:i) if u = 3, (4)
where x = 3(i − 1) + u, i.e. x is the uth nucleotide of
the ith codon, sV the sequence of the V germline gene,
and I the indicator function. The ∼ sign is generalized to
incomplete codons so that it returns a true value if there
exists a codon completion that agrees with the motif a.
Detailed formulas for the other segments are derived us-
ing the same principles and are given in the SI Appendix.
The sums in Eq. 4 (and equivalent expressions for J) can
be restricted to particular germline genes to compute the
generation probability of particular VJ-CDR3 combina-
tions.
The entries of the insertion segment N1 are calculated
using the following formula:
Mxy = PinsVD(y − x)LuaiTai+1 . . . Taj−1Rvaj , (5)
with y = 3(j − 1) + v (and x = 3(i− 1) + u as in Eq. 4).
The transfer matrix
Ta(τ, σ) =
∑
(n1,n2,σ)∼a
SVD(σ|n2)SVD(n2|n1)SVD(n1|τ)
(6)
corresponds to the probability of inserting a codon coding
for a and ending with nucleotide σ, knowing that the
previous codon ended with nucleotide τ . Lua and R
v
a are
vectors or matrices with different definitions depending
on the values of x and y modulo 3, corresponding to the
probabilities of inserting incomplete codons on the left
and right ends of the insertion segment. Eq. 5 is only
valid for j > i, but similar formulas describe the case
i = j. The precise definitions of L and R, the i = j case,
and the formulas for N and the N2 insertion segment,
which is exactly equivalent, are all given in detail in the
SI Appendix.
4FIG. 2: Monte Carlo estimate of the generation probability of
amino acid CDR3 sequences, P aagen, versus OLGA’s predictions
(mouse TRB). The horizontal lines at the lower left of the plot
represent CDR3s that were generated once, twice, etc, in the
MC sample. The one- and two-sigma curves display the devi-
ations from exact equality between simulated and computed
Pgen to be expected on the basis of Poisson statistics.
The matrix product of Eq. 5 can be calculated recur-
sively, requiring only 4× 4 matrix multiplications. Thus,
allMxy elements can be calculated in O(L2) operations,
instead of the exponential time that would be required
using brute-force summation over nucleotides in degen-
erate codons. Finally, since the sums of Eq. B2 can also
be done recursively through L×L matrix operations, the
whole procedure has O(L2) computational complexity.
III. RESULTS
A. Method validation
To verify the correctness of the OLGA code, we com-
pared its predictions for generation probabilities to those
estimated by Monte Carlo (MC) sequence generation
[29]. MC estimation is done by drawing events from a
given generative model, binning according to the result-
ing CDR3 amino acid sequence, and normalizing by the
total number of recombination events. The scatter plot of
the estimated generation probabilities for these sequences
against the values predicted by OLGA gives a direct test
of the algorithm. As MC estimation is susceptible to
Poisson sampling noise, it is important to ensure that
enough events are drawn to accurately assess the genera-
tive probabilities of individual CDR3 sequences. For this
reason, we made the comparison using a generative model
inferred from a mouse, rather than human, T cell reper-
toire, because of the significantly lower entropy of mouse
repertoires [35]. The specific model was inferred by IGoR
[25] using ∼ 70000 out-of-frame TRB sequences from a
mature mouse thymus. MC estimation was done by gen-
erating 5 × 1011 recombination events, from which the
first 106 unique CDR3 amino acid sequences are counted
to serve as a sample for the comparison. This proce-
dure provided good sequence coverage, with > 98% of se-
quences generated at least twice and > 95% of sequences
generated at least 10 times. As Fig. 2 shows for mouse
TRB (see Fig. S3 for human TRA), MC estimation and
OLGA calculation are in agreement (up to Poisson noise
in the MC estimate). The Kullback-Leibler divergence
between the two distributions, a formal measure of their
agreement, is a mere 4.82× 10−7 bits.
B. Comparison of performance with existing
methods
We compared the performance of OLGA to other
methods. Direct calculation of amino acid sequence gen-
eration probability using OLGA is orders of magnitude
faster than the two possible alternative methods: MC
estimation (as described above), or exhaustive enumera-
tion of the generative events giving rise to a given amino
acid sequence. OLGA took 6 CPU hrs to compute the
generation probabilities of the 106 amino acid sequences,
i.e. 47 seqs/CPU/sec for mouse TRB (see SI Sec. III
and Table S1 for runtimes of other loci). By compari-
son, MC estimation required 4313 CPU hrs. The scaling
for the MC estimation does not depend on the number
of queried sequences, but instead is determined by the
number of recombinations needed to control the Poisson
noise, which scales inversely with generation probability.
In practice, to determine the generation probability of a
typical sequence (which can be as low 10−20, see Fig. 3
and below), one needs to generate very large datasets,
and thus the generation probability of many sequences
cannot be calculated by the MC method.
Alternatively, one could list all possible nucleotide se-
quences that translate to a particular amino acid CDR3
and sum the generation probabilities of each nucleotide
sequence, using the IGoR algorithm [25]. Each amino
acid sequence in the mouse validation sample is, on aver-
age, coded for by 1.84 billion nucleotide sequences (and
much more for human TRB). Since IGoR computes gen-
eration probabilities of nucleotide sequences at the rate
of ∼ 60 seqs/CPU/sec, it would take ∼ 8500 CPU hrs
to compute the generation probability of a single amino
acid sequence. A systematic comparison of OLGA with
IGoR (Fig. S4) and MC estimation (Figs. S4 and S5)
as a function of the number of analysed sequences and
their CDR3 lengths shows that OLGA is faster than both
other methods for all practical purposes (see Sec. IV for
details).
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FIG. 3: Distributions of probabilities of recombination events
(P recgen), nucleotide CDR3 sequences (P
nt
gen), and CDR3 amino
acid sequences (P aagen) in different contexts. Each curve is
determined by Monte Carlo sampling of 106 productive se-
quences for the indicated locus, and computing its generation
probabilities at the three different levels. Entropies in bits
(S) are, up to a ln(2)/ ln(10) factor, the negative of the mean
of each distributions, indicated by dotted lines.
C. Distribution of generation probabilities and
diversity
V(D)J recombination produces very diverse repertoires
of nucleotide sequences, with a very broad distribution of
generation probabilities spanning up to 20 orders of mag-
nitude [6, 27]. This distribution gives a comprehensive
picture of the diversity of the process, and can be used to
recapitulate many classical diversity measures [26], and
to predict the overlap between the repertoires of different
individuals [8]. In particular, the opposite of the mean
logarithm of the generation probability, −〈log2 Pgen〉, is
equal to the entropy of the process. While previous work
focused on nucleotide sequence generation, OLGA allows
us to compute this distribution for amino acid sequences.
Fig. 3 shows the distribution of P aagen for 4 loci: human
and mouse TRB, human TRA, and human IGH, and
compares it to the distributions of nucleotide sequence
generation probabilities, P ntgen, and recombination event
probabilities, P recgen. While all these datasets are based
on DNA RepSeq, we checked that the generation prob-
ability distribution was robust to the choice of proto-
col by computing the TRB distribution for independent
datasets generated by RNA RepSeq [38, 44, 47] (Figs. S6
and S7, and SI Sec. V). The generation models used
here and elsewhere in this paper were taken from Mar-
cou et al. [25], except for the human TRB model which
was relearned using IGoR from one individual in Emer-
son et al. [9] as a check. Going from recombination events
to nucleotide sequences to amino acid sequences leads to
substantial shifts in the distribution, and corresponding
drops in entropies, as the distribution is progressively
coarse-grained. Higher generation probability of a given
receptor sequence leads to higher chance of finding it in
any given individual. Generation probabilities may be
constrasted to the scale set by the inverse of the number
of independent recombination events (estimated between
108 [31] and 1010 [22] for human TCR). Generation prob-
abilities above this limit (10−10 to 10−8 for human TCR)
can be considered “large” as the corresponding receptor
will almost surely exist in each individual [8]. Another
relevant scale to distinguish small from large generation
probabilities is given by their geometric mean (dashed
lines in Fig. 3).
D. Cross-species generation probabilities
While distinct species differ in their generation mecha-
nisms, they may yet be able to generate the same CDR3s.
Using OLGA, we computed the probabilities of produc-
ing human TRB CDR3s by the mouse recombination
model, and vice versa (details in SI Sec. VI). An im-
pressive 72.6% of human CDR3s can theoretically be
produced by mice, and 100% of mouse CDR3s can be
produced by humans. While cross-species generation
probabilities are lower than intra-species ones (Fig. S8),
they are correlated (Fig. S9). These results suggest that
CDR3s observed in the repertoires of humanized mouse
models of human diseases could be relevant for predict-
ing their presence in human repertoires as well. OLGA
allows for evaluating this potential, and could be used to
inform clinical trials.
E. Generation probability of specific TCR
We can use OLGA to assess the total fraction of the
generated repertoire that is specific to any given epitope,
simply by summing the generation probabilities of all
TRB sequences known to bind specifically to that epi-
tope:
P funcgen (epitope) =
∑
a | epitope
P aagen(a), (7)
where ”a | epitope” means that the amino acid sequence
a recognizes the epitope. Many experiments, based e.g.
on multimer sorting assays [2, 14] or T-cell culture as-
says, have established lists of epitope-specific TCR se-
quences for a number of disease-related epitopes. We
used the VDJdb database [37], which aggregates such
experiments, to compute P funcgen of all TRB known to be
reactive against several epitopes. In Fig. 4 we show re-
sults for 4 epitopes associated with Hepatitis C, and 5
epitopes associated with Influenza A. The net fraction of
the repertoire specific to these epitopes (10−7 to 10−4) is
large in the sense defined above, meaning that any indi-
vidual is likely to have many copies of reactive T cells in
their naive repertoire.
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FIG. 4: Generation probabilities of human CDR3s that re-
spond to hepatitis C and influenza A epitopes. P aagen of se-
quences that respond to an epitope are plotted as circles (color
encodes density of the points). The fraction of the repertoire
specific to each epitope (P funcgen as defined in Eq. 7 ) is obtained
as the sum of the P aagen for each of the corresponding sequences
(values plotted as triangles).
The presence of any specific TCR in the repertoire will
be affected by the recombination probability of both its
α and β chains, and also by function-dependent selective
pressures. Assessing accurately the fraction of reactive
TCRs in the blood is beyond the scope of this method.
However, it is still interesting to ask whether epitope-
specific TRB sequences had higher generation probabil-
ities than regular sequences, either because of observa-
tional biases, or because the immune system might have
evolved to make them more likely to be produced. To
answer that question, we display in Fig. 5 the P aagen distri-
bution of the sequences listed in VDJdb that are specific
to any epitope of each of 6 commonly studied viruses.
For comparison we plot the P aagen distribution of the full
TRB sequence repertoire of a healthy donor (data taken
from Emerson et al. [9]).
The viral distributions are very similar to each other,
and also to the healthy repertoire background, meaning
that the ability of a CDR3 to respond to a particular dis-
ease epitope is not strongly correlated with its generation
probability. To see whether this result was confirmed in
the case of a real infection, we repeated the same anal-
ysis on TRB RepSeq data from T-cells responding to
three different types of pathogens (fungus, bacteria, and
toxin) [1]. Consistently, we found that their distribution
of generation probability was identical to that of naive
sequences (SI Fig. S10 and SI Sec. VII).
F. Model accurately predicts the frequencies of
sequences and of groups of specific sequences
To compare OLGA’s predictions with sequence oc-
currence frequencies in real data, we used the aggre-
gated TRB repertoire of 658 human subjects described
in Emerson et al. [9] as a test resource. More specifi-
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FIG. 5: Distributions of TRB generation probabilities P aagen for
sequences in the VDJdb database that bind to any epitopes of
6 different viruses (colored curves). For comparison, we plot
(black curve) the same distribution for the unsorted TRB
repertoire of a typical healthy subject; the 2σ variance rep-
resents biological variability across multiple individuals (data
from Emerson et al. [9])
cally, we measured the frequencies in this large dataset
of the specific CDR3 sequences contained in the VDJdb
database [37], and compared them to the values assigned
by OLGA. When measuring frequencies we discarded
read count information, recording only the presence or
absence of nucleotide sequences in each individual in or-
der to eliminate effects of clonal expansion and PCR am-
plification bias, averaging over the 648 individuals in the
Emerson et al. [9] dataset to get reliable estimates of fre-
quencies. Each sequence in the VDJdb database is dis-
played as a dot in Fig. 6, and the resulting distribution
shows a strong correspondence between mean frequency
in the large data set and the predicted P aagen of that se-
quence.
We then measured the fraction of CDR3s in the ag-
gregated repertoire that is specific to epitopes associated
with 6 viruses (using lists of specific sequences in VD-
Jdb), and compared it to OLGA’s prediction, P funcgen . The
agreement was again excellent (triangles in Fig. 6). Again
we observe that most epitope-specific sequence groups
have large enough frequencies to be found in any indi-
vidual. Thus, the model can be used to predict the size
of repertoire subsets specific to any epitope, as long as
specificity data are available for this epitope.
G. Generation probability of sequence motifs
OLGA can also compute the generation probability
of any sequence motif, encoded by a string of multiple
choices of amino acids. We apply this feature to calcu-
late the net frequency of epitope-specific motifs, and of
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FIG. 6: Mean occurrence frequencies across a collection of
658 human samples of all CDR3 sequences in the VDJdb
database, plotted against their computed P aagen (dots, colored
by their density in the plot). Also, the net occurrence fre-
quency in the VDJdb database of epitope-related collections
of sequences, plotted against their computed P funcgen (triangles,
colored to identify the virus the epitope belongs to).
TABLE I: Epitope-specific TCR motifs for the Epstein-Barr
virus HLA-A*0201-BMLF1280 (BMLF) and influenza virus
HLA-A*0201-M158 (M1) epitopes from Dash et al. [2], and
their generation probabilities. Each motif was associated with
specific V/J gene choices. In the motifs we use the conven-
tions: X, any one amino acid; [A..B], any one of the listed
amino acids; X{0,}, arbitrary amino acid string.
epitope : chain : V/J CDR3 motif Pgen
BMLF :α : 5/31 CAXD[NSDA]NARLMF 1.8·10−7
BMLF :β : 20-1/1-2,1-3 CSARDX[TV]GNX{0,} 5.1·10−7
M1 :α : 27/42 CAXGGSQGNLIF 2.2·10−5
M1 :β : 19/all CASSXR[SA][STAG]X[ET]Q[YF]F 1.7·10−6
motifs that define the TRA sequence of invariant T-cells.
T-cell sequences that can bind a given epitope are of-
ten closely related to each other, and this similarity can
sometimes be partially captured by sequence motifs. We
evaluated the probabilities of motifs derived from a recent
study of CDR3 sequence specificity to a variety of epi-
topes [2]. We took two motifs corresponding to TRA and
TRB VJ-CDR3 combinations of TCRs that are known
to bind the Epstein-Barr virus HLA-A*0201-BMLF1280
(BMLF) and the influenza virus HLA-A*0201-M158 (M1)
epitopes. The motifs and generation probabilities are re-
ported in Table I.
As a second application, we estimated the probabilities
of generating a TRA chain corresponding to one of the
motifs associated with Mucosal associated invariant T
cells (MAIT) and invariant natural killer T cells (iNKT).
The motifs, which were collected from Gherardin et al.
[13], and their probabilities are shown in Table II. The
relatively high values for these motifs imply that these
invariant chains are generated with high frequency in the
primary repertoire and shared by all individuals, confirm-
ing the conclusions of Venturi et al. [42].
TABLE II: Generation probabilities of motifs corresponding
to invariant T cell (iNKT and MAIT cells) TRA chain, as-
sembled from serquence in Gherardin et al. [13].
Type V/J CDR3 motif Pgen
iNKT 10/18 CVVSDRGSTLGRLYF 1.26 · 10−6
MAIT 1-2/33 CAV[KSM]DSNYQLI[WF] 1.79 · 10−5
MAIT 1-2/12 CAVMDSSYKLIF 4.71 · 10−6
MAIT 1-2/20 CAVSDNDYKLSF 3.11 · 10−7
IV. DISCUSSION
Because the composition of the immune repertoire re-
sults from a stochastic process, the frequency with which
distinct T- and B-cell receptors are generated is a quan-
tity of primary interest. This frequency is computa-
tionally difficult to evaluate because each amino acid se-
quence can be created by a very large number of recom-
bination events. Our tool overcomes that challenge with
dynamic programming, allowing it to process ∼ 50 se-
quences per second on a single CPU. In its current state
OLGA can compute the probabilities of CDR3 sequences
and motifs, with or without V/J restriction, of 4 chain
loci (human and mouse TRB, human TRA, and human
IGH), but the list can readily be expanded by learning
recombination models for other loci and species using
IGoR [25] which shares the same model format. Obvious
additions include the light chains of BCR [40], and more
mouse models. While the algorithm evaluates the prob-
ability of single chains, recent analyses show that chain
pairing in TCR is close to independent [5, 15]. The prob-
ability of generating a whole TCR receptor can thus be
computed by taking the product over the two chains.
OLGA can be used to compute baseline receptor fre-
quencies and to identify outlying sequences in repertoire
sequencing datasets. In Elhanati et al. [8] we used it
to shed light on the question of public repertoires —
composed of sequences shared by many individuals —
and predict quantitatively its origin by convergent re-
combination [23, 24, 41]. Deviations from the baseline
expectancy have been used to identify disease-associated
TCR from cohorts of patients [9, 10, 12, 34, 48], and to
identify clusters of reactive TCRs from tetramer experi-
ments [14] and vaccination studies [30]. Such estimates
could be made faster and more reliable by OLGA, es-
pecially for rare sequences, and without the need for a
negative control cohort [29]. In the future, OLGA could
be useful in vaccine and therapy design by focusing atten-
8tion on clonotypes that are likely to be present in every
individual.
We applied OLGA to an experimental database of
TCR responding to a variety of disease-associated epi-
topes. These selected TCR do not differ in their gener-
ation probabilities from those of random TCR found in
the blood of healthy donors. However, some viral epi-
topes bind a much larger fraction of the repertoire than
others. This observation has potentially important con-
sequences for vaccine design. Since vaccine epitopes stim-
ulate TCR in a pre-existing repertoire, epitopes targeting
receptor sequences that are more likely to be generated
will have a higher success rate in a wider range of in-
dividuals. OLGA can be used to identify such epitopes
by computing their specific repertoire fractions, P funcgen .
While our examples are restricted to TCR, OLGA can
also handle BCR and could be used to compute the gen-
eration probabilities of BCR precursors of highly reactive
or broadly neutralizing antibodies, and thus guide vac-
cine design in that case as well. The algorithm does not
yet handle hypermutations, and extending it to include
them would be a useful development.
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Appendix A: Additional matrix definitions for VDJ algorithm
Recall that the generative VDJ model is defined as:
P recgen(E) = PV(V )PDJ(D,J)PdelV(dV |V )PdelJ(dJ |J)PdelD(dD, d′D|D)PinsVJ(`VD)p0(m1)
[
`VD∏
i=2
SVD(mi|mi−1)
]
×PinsDJ(`DJ)q0(n`DJ )
[
`DJ−1∏
i=1
SDJ(ni|ni+1)
]
,
(A1)
with
P aagen(a1, . . . , aL) =
∑
σ∼a
P ntgen(σ1, . . . , σ3L) =
∑
E→σ∼a
P recgen(E). (A2)
As described in the main text, the dynamic programming algorithm can be summarized by the summation over the
positions x1, x2, x3, and x4 of the following matrix multiplication:
P aagen(a1, . . . , aL) =
∑
x1,x2,x3,x4
Vx1Mx1x2 ×
∑
D
[D(D)x2x3N x3x4J (D)x4] . (A3)
The interpretation of the left (subscript) and right (superscript) indices are detailed in the main text, and schema-
tized in Fig. S1. The sums are performed iteratively using matrix multiplications, as detailed in Fig. ??. As in
the main text, the nucleotide indices will often be suppressed along with the implicit dependence on the amino acid
sequence (a1, . . . , aL). For a given nucleotide position xj , it will be convenient to refer to the amino acid index, and
the position in the codon (from both the left and the right), so we introduce the following (graphically shown in the
cartoon below): xj = 3(ij − 1) + uj , and u, so that ij encodes the codon that index xj belongs to, and uj its position
(from 1 to 3) within that codon, while u∗j denotes the position taken from the right of index xj + 1 within its codon,
so that u∗j = 2 if uj = 1, u
∗
j = 1 if uj = 2, and u
∗
j = 3 if uj = 3.
We now define the explicit forms for each of the matrices (note that we retain the indexing xj from Eq A3):
a. Vx1
Contribution from the templated V genes. Vx1 can be a 1x1 or 1x4 matrix depending on u1. sV is the sequence of
the V germline gene (read 5 ′ to 3 ′ ) from the conserved residue (generally the cysteine C) to the end of the gene. lV
is the length of sV . These equations are given in the main text.
Vx1(σ) =
∑
V
PV(V )PdelV(lV − x1|V )I(sVx1 = σ)I(sV1:x1 ∼ a1:i1) if u1 = 1,
Vx1(σ) =
∑
V
PV(V )PdelV(lV − x1|V )I((sV1:x1 , σ) ∼ a1:i1) if u1 = 2,
Vx1 =
∑
V
PV(V )PdelV(lV − x1|V )I(sV1:x1 ∼ a1:i1) if u1 = 3.
(A4)
b. Mx1x2
Contribution from the non-templated N1 insertions (VD junction). Mx1x2 is defined as the product of transfer
matrices, and can be a 1x1, 1x4, 4x1, or 4x4 matrix depending on u1 and u2. The transfer matrices are defined by the
summed contributions of the Markov insertion model of all codons consistent with the amino acid a (thus summations
12
are over nucleotides y, y1, and y2 to consider all allowed codons):
Ta(τ, σ) =
∑
(y1,y2,σ)∼a
SVD(σ|y2)SVD(y2|y1)SVD(y1|τ) (A5)
Fa(τ, σ) = SVD(σ|τ)I[∃σ′, σ′′ s.t. (σ, σ′, σ′′) ∼ a] (A6)
Da(τ, σ) =
∑
(y1,y2,σ)∼a
SVD(y2|y1)SVD(y1|τ) (A7)
lTa(τ, σ) =
∑
(τ,y,σ)∼a
SVD(τ |y)p0(y) (A8)
lDa(τ, σ) =
∑
(τ,y,σ)∼a
p0(y) (A9)
If i2 > i1:
Mx1x2 = PinsVD(x2 − x1)Lu1ai1Tai1+1 . . . Tai2−1R
u2
ai2
(A10)
where:
Lu1ai1 =

lTai1 if u1 = 1
diag(p0) if u1 = 2
S−1VDp0 if u1 = 3
and Ru2ai2 =

Fai2 if u2 = 1
Dai2 if u2 = 2
Tai2
~1 if u2 = 3
(A11)
If i1 = i2:
Mx1x2 = PinsVD(x2 − x1)×
u2 = 1 u2 = 2 u2 = 3
u1 = 1 1 0 0
u1 = 2 lDai1 1 0
u1 = 3 lTai1
~1 diag(p0)~1 1
(A12)
c. D(D)x2x3
Contribution from the templated D genes. D(D)x2x3 can be a 1x1, 1x4, 4x1, or 4x4 matrix depending on u∗2 and
u∗3. s
D is the sequence of the D germline gene (read 5 ′ to 3 ′ ) with length lD.
D(D)x2x3(τ, σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[sDdD+1 = τ ]I[sDlD−d′D = σ]I[s
D
dD+1:lD−d′D ∼ ai2:i3 ] if u
∗
2 = 1 and u
∗
3 = 1,
D(D)x2x3(τ, σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[sDdD+1 = τ ]I[(sDdD+1:lD−d′D , σ) ∼ ai2:i3 ] if u
∗
2 = 1 and u
∗
3 = 2,
D(D)x2x3(τ) =
∑
d′D
PdelD(dD, d
′
D|D)I[sDdD+1 = τ ]I[sDdD+1:lD−d′D ∼ ai2:i3 ] if u
∗
2 = 1 and u
∗
3 = 3,
(A13)
D(D)x2x3(τ, σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[sDlD−d′D = σ]I[(τ, s
D
dD+1:lD−d′D ) ∼ ai2:i3 ] if u
∗
2 = 2 and u
∗
3 = 1,
D(D)x2x3(τ, σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[(τ, sDdD+1:lD−d′D , σ) ∼ ai2:i3 ] if u
∗
2 = 2 and u
∗
3 = 2,
D(D)x2x3(τ) =
∑
d′D
PdelD(dD, d
′
D|D)I[(τ, sDdD+1:lD−d′D ) ∼ ai2:i3 ] if u
∗
2 = 2 and u
∗
3 = 3,
(A14)
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D(D)x2x3(σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[sDlD−d′D = σ]I[s
D
dD+1:lD−d′D ∼ ai2:i3 ] if u
∗
2 = 3 and u
∗
3 = 1,
D(D)x2x3(σ) =
∑
d′D
PdelD(dD, d
′
D|D)I[(sDdD+1:lD−d′D , σ) ∼ ai2:i3 ] if u
∗
2 = 3 and u
∗
3 = 2,
D(D)x2x3 =
∑
d′D
PdelD(dD, d
′
D|D)I[sDdD+1:lD−d′D ∼ ai2:i3 ] if u
∗
2 = 3 and u
∗
3 = 3
(A15)
where dD = lD − (x3 − x2)− d′D
d. N x3x4
Contribution from the non-templated N2 insertions (DJ junction). N x3x4 is defined as the product of transfer
matrices, and can be a 1x1, 1x4, 4x1, or 4x4 matrix depending on u∗3 and u
∗
4. The transfer matrices are defined by the
summed contributions of the Markov insertion model of all codons consistent with the amino acid a (thus summations
are over nucleotides y, y1, and y2 to consider all allowed codons):
T ′a(τ, σ) =
∑
(σ,y2,y1)∼a
SDJ(σ|y2)SDJ(y2|y1)SDJ(y1|τ) (A16)
F ′a(τ, σ) = SDJ(σ|τ)I[∃σ′, σ′′ s.t. (σ′′, σ′, σ) ∼ a] (A17)
D′a(τ, σ) =
∑
(σ,y2,y1)∼a
SDJ(y2|y1)SDJ(y1|τ) (A18)
lT ′a(τ, σ) =
∑
(σ,y,τ)∼a
SDJ(τ |y)q0(y) (A19)
lD′a(τ, σ) =
∑
(σ,y,τ)∼a
q0(y) (A20)
If i4 > i3:
N x3x4 = PinsDJ(x4 − x3)L′u
∗
3
ai3
T ′ai3+1 . . . T
′
ai4−1
R′u
∗
4
ai4
(A21)
where:
L′u
∗
3
ai3
=

F ′ai3 if u
∗
3 = 1
D′ai3 if u
∗
3 = 2
T ′ai3
~1 if u∗3 = 3
and R′u
∗
4
ai4
=

lT ′ai4 if u
∗
4 = 1
diag(q0) if u
∗
4 = 2
S−1DJq0 if u
∗
4 = 3
(A22)
If i3 = i4:
N x3x4 = PinsDJ(x4 − x3)×
u∗4 = 1 u
∗
4 = 2 u
∗
4 = 3
u∗3 = 1 1 lD
′
ai3
lT ′ai3
~1
u∗3 = 2 0 1 diag(q0)~1
u∗3 = 3 0 0 1
(A23)
e. J (D)x4
Contribution from the templated J genes. J (D)x4 can be a 1x1 or 4x1 matrix depending on u∗4. sJ is the sequence
of the J germline gene (read 5 ′ to 3 ′ ) and lJ gives the length of the sequence up to the conserved residue (generally
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FIG. S1: Schematic of the partitioning of an amino acid sequence into sections for the purpose of constructing the probability
matrices underlying the dynamic programming method for computing its net generation probability. The indexing conventions
are also highlighted.
either F or W).
J (D)x4(τ) =
∑
J
PD,J(DJ)PdelJ(dJ |J)I(sJdJ+1 = τ)I(sJdJ+1:lJ ∼ ai4:L) if u∗4 = 1,
J (D)x4(τ) =
∑
J
PD,J(DJ)PdelJ(dJ |J)I((τ, sJdJ+1:lJ ) ∼ ai4:L) if u∗4 = 2,
J (D)x4 =
∑
J
PDJ(D,J)PdelJ(dJ |J)I(sJdJ+1:lJ ) ∼ ai4:L) if u∗4 = 3.
(A24)
where dJ = lJ − 3L− x4 − 1
Appendix B: VJ recombination
The model used for VJ recombination is quite similar to the model for VDJ recombination with the main differences
being the lack of a D segment and an N2 insertion segment. However, a strong correlation between V and J templates
is observed in the TRA chain, so we include a joint V, J distribution to allow for this correlation. Due to this similarity,
the algorithm used to compute Pgen is very similar. The VJ generative model is:
P recgen(E) = PVJ(V, J)PdelV(dV |V )PdelJ(dJ |J)× PinsVJ(`VJ)p0(m1)
[
`V J∏
i=2
SVJ(mi|mi−1)
]
(B1)
with nucleotide and amino acid Pgens being defined the same as for the VDJ recombination model (Eq A2). The
dynamic programing algorithm also has a similar form to Eq A3, and can be summarized as (retaining all notation
conventions from before):
Pgen(a1, . . . , aL) =
∑
x1,x2
∑
J
V(J)x1Mx1x2J (J)
x2 (B2)
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N1 insertions:
Vx1
J x4(D)
PinsDJ(`DJ), q0(n`DJ),
SDJ(ni|ni+1)
PinsVD(`VD), p0(m1),
SVD(mi|mi 1)
N2 insertions:
PV(V )PdelV(dV |V )
PDJ(D, J)PdelJ(dJ |J)
PdelD(dD, d
0
D|D)D alignment:
 J alignment:
 V alignment:
Pgen =
X
x1,x2,x3,x4
Vx1Mx1x2
X
D
Dx2x3(D)N x3x4J x4(D)
X
x1
Vx1Mx1x2
X
x4
N x3x4J x4(D)
X
x3,x4
X
D
Dx2x3(D)N x3x4J x4(D)
FIG. S2: Schematic of the OLGA VDJ algorithm implementation breakdown. Each of the 5 segments (V, N1, D, N2, J),
and their associated model contributions, are considered from the edges of the CDR3 towards the inside. This is done both
from the left side (V, N1) and the right side (D, N2, J) of the read to efficiently account for the correlations for the D and J
genes. Including inner segments (N2, D, N2) requires summing over an index, indicating that all possible allowed start and
end positions of the segment are considered.
a. V(J )x1
Contribution from the templated V genes.
V(J)x1(σ) =
∑
V
PVJ(V, J)PdelV(lV − x1|V )I(sVx1 = σ)I(sV1:x1 ∼ a1:i1) if u1 = 1,
V(J)x1(σ) =
∑
V
PVJ(V, J)PdelV(lV − x1|V )I((sV1:x1 , σ) ∼ a1:i1) if u1 = 2,
V(J)x1 =
∑
V
PVJ(V, J)PdelV(lV − x1|V )I(sV1:x1 ∼ a1:i1) if u1 = 3.
(B3)
b. Mx1x2
Contribution from the non-templated N insertions (VJ junction). Mx1x2 is identical to the definition of Mx1x2
from the VDJ algorithm (except using the parameters SVJ, PinsVJ, and p0 from a VJ recombination model).
c. J (J)x2
Contribution from the templated J genes.
J (J)x2(τ) = PdelJ(dJ |J)I(sJdJ+1 = τ)I(sJdJ+1:lJ ∼ ai2:L) if u∗2 = 1,
J (J)x2(τ) = PdelJ(dJ |J)I((τ, sJdJ+1:lJ ) ∼ ai2:L) if u∗2 = 2,
J (J)x2 = PdelJ(dJ |J)I(sJdJ+1:lJ ) ∼ ai2:L) if u∗2 = 3.
(B4)
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FIG. S3: Monte Carlo estimate of the generation probability of amino acid human TRA CDR3 sequences, P aagen , versus OLGA’s
calculation. The horizontal lines at the lower left of the plot represent CDR3s that were generated once, twice, etc, in the MC
sample. The one- and two-sigma curves display the deviations from exact equality between simulated and computed Pgen to
be expected on the basis of Poisson statistics.
where dJ = lJ − 3L− x− 1
This algorithm is validated in the same manner to the VDJ algorithm, i.e. comparing to Monte Carlo (MC)
estimation (Fig S3).
Appendix C: Dependence on model parameters and structure
In order to efficiently compute the summation in Eq. A3 the summations of the model contributions from each
of the 5 segments of a CDR3 (V genomic, N1 insertions, D genomic, N2 insertions, and J genomic) are performed
in a specific order (summarized in Fig S2). Specifically, we start at the left and right ends of the CDR3 read and
move inwards, summing over positional indices at each step. As the D and J segments are correlated, it is useful
to consider the V and N1 contributions separately from the D, N2, and J and to do the final summation over the
index x2 after the D, N2, and J components are summed over all D alleles (notice the D dependencies in Fig S2).
This breakdown is useful to highlight the most computationally intensive steps: N2 insertions and the D alignment.
These steps (along with the N1 insertions) require considering that the associated segment could begin and end at
each allowed position. This is mathematically seen as the summation over positions and computing a matrix indexed
by two indices, leading to an O(L2) complexity. The N2 insertions and D alignments are further aggravated due to
model correlations between the D and J genes requiring repeating the steps for N2 insertions and D alignment for each
D allele. The runtime of OLGA is thus most sensitive to the maximum number of N2 insertions and the length and
number of the D alleles. The effects of varying these parameters is best illustrated by comparing runtimes for mouse
TRB, human TRB, and human IGH models (Table S1). In a similar fashion, the most computationally intensive
TABLE S1: Model comparison
Species/Chain max insertions # D alleles Average computation speed
Mouse TRB 11 2 70.4 seqs/CPU second
Human TRB 30 3 35.6 seqs/CPU second
Human IGH 60 35 2.05 seqs/CPU second
step of computing Pgen of a VJ model (e.g. human TRA) is the insertion step, and due to correlations between the V
and J genes this is repeated for each J allele in a similar fashion as the D alleles However, as the J region of a human
TRA is fairly large, many of these J genes can be excluded from alignment (if they contribute 0 probability), yielding
the much faster computation rate of 184 seqs/CPU second.
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FIG. S4: A) Computational performance of OLGA as a function of CDR3 length. We compare performance averaged over a
sample of human TRB amino acid CDR3 sequences to the worst case scenario of CDR3 sequences composed of fully ambiguous
amino acids X. In both cases the time for a single sequence increases roughly linearly (i.e. less than the algorithmic worst case
of O(L2)). B) Computational performance of different Pgen methods as a function of CDR3 length (log scale). The IGoR and
OLGA runtimes are determined by running over the same statistical sample of human TRB sequences. OLGA runs over the
translated amino acid CDR3 sequences while IGoR runs over nucleotide CDR3 (dashed blue line). In order to compare OLGA
to how long it would take IGoR to compute Pgen of amino acid CDR3s we estimate by multiplying the IGoR runtime of single
nucleotide sequences (dashed blue line) by the number of nucleotide sequences that translate to the given amino acid sequence
(yielding the solid blue line). Monte Carlo runtime is estimated for a dataset of 100,000 sequences with an estimated coverage
of 66% of sequences having at least one count. OLGA vastly outperforms both direct enumeration (est. IGoR) and Monte
Carlo.
Appendix D: Timing, performance, model dependence
In order to analyze OLGA’s computational performance as a function of CDR3 length, and to compare to other
hypothetical methods, we use the human TRB model as an example.
As discussed in the previous section, the most computationally intensive steps of OLGA (N1, N2, and D) require at
most O(L2) operations. In practice, OLGA’s scaling of the computation speed as a function of CDR3 length, even for
the worst case sequences, i.e. fully ambiguous amino acids of a given length, is closer to linear in the relevant regime
due to the finite parameterization of the model (maximum number of insertions, maximum size of D sequences, etc).
This is shown in Fig S4A.
We also compare OLGA to runtimes of IGoR (i.e. direct enumeration of recombination events) and a hypothetical
Monte Carlo computation (Fig S4). As we will explain, neither the IGoR nor the MC are precise comparisons to
OLGA, yet OLGA is faster than either.
The IGoR runtimes are for nucleotide sequences not amino acid sequences. In order for IGoR to compute the Pgen
of an amino acid sequence, it would need to compute and sum the Pgen of each nucleotide sequence that codes for the
amino acid sequence. These sequences can be enumerated for extremely short CDR3 lengths, however the number
explodes exponentially in CDR3 length. Even for a CDR3 length of 4, by enumerating all nucleotide sequences for
an amino acid sequence IGoR computes 0.33 seqs/CPU second compared to the 122 seqs/CPU second for OLGA.
For longer CDR3 lengths we approximate how long IGoR would take by computing the average number of CDR3
nucleotide sequences per CDR3 amino acid sequence for a given length. OLGA not only heavily outperforms this
exponential blowup, but actually outperforms IGoR when IGoR is computing a single nucleotide sequence of a given
amino acid sequence.
The Monte Carlo runtime estimate comes from the setup of estimating the Pgen of 100,000 sequences. These Pgen
would be estimated by simulating enough recombination events such that 66% of CDR3 sequences of a given length
would be expected to have at least one count. There is a CDR3 length scaling due to the trend that shorter sequences
tend to have higher Pgen (Fig S5B). The Pgen estimated using this methodology will be extremely noisy (Poisson noise
on the expected number of counts) and not even give reliable estimates for many sequences.
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FIG. S5: A) The runtime of Mont Carlo Pgen estimation scales as 1/Pgen while OLGA will scale with the number of sequences.
This predicts a number of sequences for the ‘crossing point’ where the runtime of Monte Carlo Pgen estimation is comparable
to OLGA Pgen for sequences with Pgen above some cutoff. For datasets with more sequences than these curves, Monte Carlo
estimation may be faster (depending on the level of Poisson noise considered tolerable), while below these curves OLGA is
always faster. We plot this as a function of CDR3 length where the Pgen cutoffs are determined to ensure that on average some
fraction (66%, 90%, 95%, and 99%) of the sequences at that length get covered by the Monte Carlo estimation. B) log10(Pgen)
probability density distributions for a few examples of CDR3 lengths. These curves are used to determine the MC Pgen cutoffs
per CDR3 length by determining, for a given curve, when the area under the curve and right of a Pgen cutoff matches the
sequence coverage fraction.
It is true that the computation time for MC estimates scale as 1/Pgen and not with the number of sequences. Thus,
there is a hypothetical number of sequences when MC is faster than OLGA if we are willing to accept noisy estimates
and to entirely miss some fraction of the CDR3s. This ‘crossing point’ number of sequences is plotted in Fig S5A
and corresponds to completely unrealistic numbers of sequences, highlighting the fact that OLGA will not only give
a more reliable Pgen, even for very unlikely sequences, but is also much faster than MC even for short, high Pgen,
sequences. So, even overlooking the drawbacks and imprecision of MC estimation, for plausible sized datasets OLGA
is still dramatically faster than MC.
Appendix E: Generation probability distributions from RNA-derived repertoires
The analyses described in the main text were mostly concerned with datasets derived by sequencing the genomic
DNA contained in a sample of immune cells to directly obtain sequences of the rearranged TCR genes. Immune
repertoires can alternatively be obtained by sequencing the mRNA expressed from the same genes, and many such
RNA-based data sets exist. Given a TCR sequence, OLGA evaluates the probability of the primitive recombination
event (or events) that must have occurred to create the initial T cell carrying that sequence, and the applicability
of OLGA is independent of how the sequence was obtained (i.e. from DNA or RNA sequencing). OLGA relies
on the availability of a suitable recombination model but that model is thought to vary very little with time (and
disease status) for each individual subject and only moderately from individual to individual in a given species. The
probability that a given sequence, once generated in a primitive event, will be captured in a sequencing experiment
is at best roughly constant across sequences, and may vary substantially between different capture protocols.
For these reasons, it is interesting to investigate how these generation probability distributions vary across CDR3
repertoires obtained using different sequencing protocols in different biological contexts. In Fig. S6 we plot the results
of running OLGA on a few recently published human TRB repertoires that were obtained using RNA sequencing.
These samples comprise a study of patients with glioblastoma disease (Sims et al. [38]), a study of patients with
Crohn’s disease and ulcerative colitis (Wu et al. [47]), and a comprehensive study of the dynamics of TCRs in healthy
individuals (Wang et al. [44]). Fig. S6 shows the generation probability distribution of data sets from these three
sources, for comparison plotted together with the distribution obtained from DNA sequencing of the large human
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FIG. S6: Generation probability distributions for TRB CDR3 sequences taken from three different sources (Sims et al. [38],
Wu et al. [47], Wang et al. [44]), compared to DNA RepSeq data from Emerson et al. [9] (black curve with standard deviation),
using a model inferred from [9]. All distributions have approximately the same shape, with a slight bias in the data from
Sims et al. [38], indicating how robust is the distribution. Data from Sims et al. are identified in the SI of [38] as IDs N01
(normal cortex) and G10 (glioblastoma). Data from Wang et al. is identified by Short Read Archive (SRA) accession numbers
SRR030702 (naive) and SRS007450 (memory). See also Fig. S7.
sample of Emerson et al. [9]. As can be seen, two of the three RNA data sets give results quite consistent with the
DNA-based results. The glioblastoma data (Sims et al. [38]) gives a distribution broadly similar to the other three,
but with a systematic shift to higher frequency of occurrence of lower generation probability sequences. We do not
know whether or not this difference is biologically significant, or an artifact of the used protocol. The difference
does not seem to be due to sampling depth, as can be seen in Fig. S7, where multiple samples from Sims et al. [38]
are plotted: the distributions derived from smaller samples are noisier than, but statistically consistent with, the
distributions based on the largest samples.
Appendix F: Cross-species Pgen
TCR sequence repertoires are different in detail between species, both because the genomic templates differ and
because of differences in the parameters of the recombination process itself. As a result, there are clear interspecies
differences in CDR3 length distribution and amino acid composition. Nevertheless, the TRB CDR3 regions of different
vertebrate species have the same overall structure and the same conserved residues at the two ends of the CDR3. As a
result, a CDR3 from one species usually has a non-zero probability to be produced within a different species, a fact of
some interest in the context of studies of cross-species sharing of T cell types. We explored this concept with OLGA
by feeding TRB CDR3s produced by the human generation model to a mouse generation model and vice versa. The
resulting generation probability distributions are plotted in Fig. S8.
The sequences that are produced in one species have substantially lower probability of being generated in the other
species (Fig. S8). The effect is strongest for finding human sequences in a mouse repertoire (compare the black dashed
curve with red solid curve): the bulk of the human sequences have extremely low generation probabilities in the
mouse model. The effect is less strong for finding mouse sequences in a human repertoire (compare the red dashed
curve with the black solid curve): a small fraction of the mouse sequences have generation probabilities that are as
high as the highest generation probabilities of human sequences. The results are not symmetric - while the mouse
TRBs processed using the human model have a distinct bi-model distribution, the human TRBs have a very flat and
low mouse generation probabilities. Furthermore, mouse TRB sequences always have a non-zero probability of being
generated in a human TRB context, however 27.4% of human TRB sequences have Pgen = 0 as defined by a mouse
TRB model. This asymmetry is primarily due to differences in the insertion profiles (humans may have many more
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FIG. S7: Generation probability distributions for different samples from Sims et al. [38], compared to DNA RepSeq data from
Emerson et al. [9] (black curve with standard deviation), using a model inferred from [9]. Color indicate sample size: larger
datasets are blue, while small ones are red. The only effect of decreasing the sample size is increasing the noise, but the shape
stays the same. All TRB datasets from the study are plotted.
inserted N1 and N2 nucleotides) and by extension CDR3 length. Nonetheless, these results suggest that there will be
a non-negligible amount of sharing, entirely due to chance statistics, of CDR3 sequences between mouse and human
repertoires. A more detailed view of this structure can be seen in a scatter plot of the generation probabilities between
the two (Fig. S9). While there are many sequences with high generation probabilities in both the actual generative
model and the cross species model, the cross species generation probabilities are much more variable and span many
orders of magnitude, without much correlation to the correct species model.
Appendix G: Generation probability distributions from additional pathogen response datasets
In the main text, we displayed the distribution of generative probabilities for T cells known to respond to various
pathogens, and even specific epitopes of particular pathogens. The T cell sequences are taken from databases that
compile results from multiple experiments. We found that these distributions were, within statistical noise, indistin-
guishable from the background Pgen distribution of PBMCs drawn from the blood. In other words, it would seem that
there is no correlation between ease of generation of a T cell and its likelihood to respond to a particular pathogen or
epitope. A defect of this analysis is that the database agglomerates sequences from different experimental protocols,
so that there is no way of knowing what biases might have affected the inclusion of any given sequence in the database.
Obviously, it would be better to do a single well-controlled experiment in which T cells from a single donor are stim-
ulated to expand by selected pathogens, and the expanded T cells sequenced. Such an experiment was reported by
Becattini et al. [1] several years ago. In their experiment, CD4+ helper T cells were separated from peripheral blood
samples, autologous monocytes from the same samples were incubated with three different pathogens (a fungus, a
bacterium, and a toxin) in order to load pathogen epitopes, and helper T cell subsamples (typically containing several
million T cells, and hundreds of thousands of clonotypes) were incubated with the prepared monocytes (this was
done independently for samples from several donors). The T cells in the various samples that had proliferated under
this treatment were separated out (typically yielding millions of cells) and their TRB sequences obtained using the
Adaptive Biotechnology genomic DNA protocol. The result is a collection of lists of clones (defined by CDR3 amino
acid sequence) from the blood of individual donors that can be said to have expanded under stimulation by the three
different pathogens. The responses obtained in this way are quite polyclonal, with a few thousand clonotypes in each
list of responding clones (the polyclonality perhaps being due to the fact that stimulation is with preparations of
whole pathogens, as opposed to particular pathogen peptides). The Pgen distributions of the pathogen–responsive
clones for different individuals and pathogens are plotted in Fig. S10. They are indistinguishable from the background
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FIG. S8: Probability densities of log10(Pgen) for sequences generated from mouse TRB and human TRB models. The Pgen of
a sequence is computed using either a mouse TRB model or a human TRB model depending on the curve. Models are based
on data from Emerson et al. [9] for human TRB and Sethna et al. [36] for mouse TRB.
Pgen distribution derived from blood samples of healthy individuals, which is also plotted (along with its two-sigma
variance across a population of individuals) for reference. These data further strengthen the conclusion that pathogen
response activity is uncorrelated with Pgen.
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FIG. S9: Scatter plots of CDR3 sequence repertoires across their Pgen values as determined by a human TRB model or a mouse
TRB model. The sequence repertoires are Monte Carlo samples from A) a human TRB model or B) a mouse TRB model.
Projections of the scatter plots onto the two axes reproduce the distributions displayed in Fig. S8. Models are based on data
from Emerson et al. [9] for human TRB and Sethna et al. [36] for mouse TRB.
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FIG. S10: Pgen distributions for human CD4+ T cell repertoires that have been incubated with three different pathogens
(Becattini et al. [1]): the fungus Candida Albicans (CA), the bacterium Mycobacterium Tuberculosis (MT), and a toxin
protein Tetanus Toxoid (TT). For comparison, the background distribution from human peripheral blood TRB sequences from
Emerson et al. [9] (with its two sigma variation across multiple individuals) is also plotted. The plotted curves are averages
over data from individual donors. The sizes of the responsive T cell repertoires are quite variable: the CA dataset has 39934
clonotypes from 5 donors, the TT dataset has 26573 clonotypes from 4 donors, and the MT dataset has 5082 clonotypes from
2 donors. The generation model was infered from Emerson et al. [9].
